Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Quincy S Chu

doi:10.1177/1758835919895756

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Ther Adv Med Oncol. 2020 Jan 23:12:1758835919895756. doi: 10.1177/1758835919895756. eCollection 2020.

Author

Quincy S Chu¹

Affiliation

¹ Division of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada.

Abstract

The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driver mutations in non-small cell lung cancer. These driver mutations can be categorized into mutations in or near the kinase domain, gene amplification or fusion. In this review, BRAF V600E, EGFR and HER-2 exon 20 mutation, FGFR1-4, K-RAS, MET, neuregulin-1, NRTK, PI3K/AKT/mTOR, RET and ROS1 gene aberration and their therapeutics will be discussed.

Keywords: BRAF mutation; EGFR exon 20; HER-2; K-RAS; MET amplification; MET exon 14; NRG; NTRK; driver mutations; non-small cell lung cancer (NSCLC).

Publication types

Review